Overview

Phase 1, TAK-648, Single-Rising Dose Study

Status:
Completed

Trial end date:
2015-07-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the safety, tolerability and pharmacokinetics of TAK-648 when administered as a single oral dose of TAK-648 solution at escalating dose levels in healthy participants.

Phase:

Phase 1

Details

Lead Sponsor:

Takeda

Treatments:

Pharmaceutical Solutions